News
Sun Pharmaceutical Industries is discontinuing two trials of its drug candidate SCD-044 for moderate to severe as psoriasis ...
Citi analysts increased the price target on Kymera Therapeutics, Inc. (NASDAQ:KYMR) from $52 to $60 and kept a “Buy” rating.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback